Surrozen updates pipeline; cash $75.8M, net loss improves; SZN-043 and SZN-1326 timelines

Surrozen, Inc./DE

Cash, equivalents and marketable securities $75.8M at Dec 31, 2022, down from $123.5M; runway into H2 2024.
Collaboration revenue $12.5M from Boehringer Ingelheim deal; net loss improved to $36.0M from $54.6M in 2021.
SZN-043: Phase 1a in chronic liver disease enrolled first patient, data expected end 2023; Phase 1b in severe alcoholic hepatitis in 2024.
SZN-1326: expect to re-initiate Phase 1a in healthy volunteers mid-2023 with lower dose; Phase 1b UC data H2 2024.
Boehringer partnership for SZN-413: potential $10M milestone upon lead candidate nomination by end 2023.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.